Market Cap 4.22B
Revenue (ttm) 627.24M
Net Income (ttm) -177.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28.22%
Debt to Equity Ratio 0.31
Volume 680,000
Avg Vol 1,915,782
Day's Range N/A - N/A
Shares Out 184.69M
Stochastic %K 87%
Beta 0.09
Analysts Strong Sell
Price Target $72.24

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 317 5050
Address:
2101 Cottontail Lane, Somerset, United States
Night_Owl_Biotech
Night_Owl_Biotech Dec. 23 at 10:19 PM
Commercial-stage oncology focused bio valuation related data points for those with market caps north of $1.5B $SNDX is up sharply the last 5 months. In early August 2025, investors could buy SNDX for $10/share. Since the ASH presentations, the market appears more confident longer-term revenue estimates are attainable. All the same, at $22 a share SNDX still trades at meaningfully lower multiples of projected revenues than the others in this specific peer group. $INCY could, in theory, buy SNDX for 4.0X FY29 revenue estimates consistent with peer M&A revenue multiples paid. Should INCY maintain a 4.2X FY29 revenue multiple the acquisition would, again in theory, be accretive to INCY shareholders. $LEGN valuation continues to suffer in light of $JNJ recent combo drug data that meaningfully outperformed Carvykti in R/R MM. It's been 2 weeks & we're unaware of any reduction in LEGN analyst projections (we could be wrong). This is not investment advice (especially LEGN). $XBI
1 · Reply
The_Scientist
The_Scientist Dec. 22 at 9:08 PM
$LEGN remember at these prices you will hold gold. Don't give up 🙏🏽
0 · Reply
doodoodeity
doodoodeity Dec. 22 at 4:07 PM
$LEGN taking a starter here, more near 21
0 · Reply
Nikolay27
Nikolay27 Dec. 21 at 6:17 PM
0 · Reply
Nikolay27
Nikolay27 Dec. 21 at 6:16 PM
0 · Reply
The_Scientist
The_Scientist Dec. 19 at 6:42 PM
$LEGN patience family the crackheads at Wall Street will allow it to run up soon. Just hold through difficult times 🙏🏽. Stay strong.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:54 PM
Actionable Trade Alert for $LEGN: Market Context: $LEGN is currently trading at $21.28, significantly below its 60-day high of $34.8, indicating potential for upward movement. The RSI at 15.47 suggests the stock is oversold, which may lead to a price correction. Directional Bias: The stock's proximity to its 60-day low of $21.19 and the low RSI indicates a strong potential for a rebound. Additionally, both the 30-day (27.2) and 50-day (29.26) moving averages are well above the current price, which could act as resistance levels. Trade Plan: - Suggested Entry: $21.30 - Stop Loss: $20.50 (approximately 3.75% risk) - Take Profit Targets: 1. $24.00 (Target 1, 12.7% ROI) 2. $26.00 (Target 2, 22.5% ROI) 3. $25.00 (Target 3, 17.6% ROI) With this plan, we aim for a minimum of 17% ROI on the third target while managing risk effectively. https://privateprofiteers.com
0 · Reply
WolfofWallasey
WolfofWallasey Dec. 19 at 4:46 PM
Almost Christmas My current plays are $MIGI which I think could rip faces any moment $CRWD safe long term set and forget $LEGN set and forget and she’s about to become profitable Peace ✌️
0 · Reply
Tigerpicko
Tigerpicko Dec. 19 at 3:52 PM
$LEGN bring on Q1 2026
0 · Reply
Himster
Himster Dec. 19 at 1:46 PM
$LEGN company is projected to be profitable next year..
0 · Reply
Latest News on LEGN
Cancer Study Buoys These Small Biotechs

Dec 9, 2025, 3:31 PM EST - 15 days ago

Cancer Study Buoys These Small Biotechs

ACLX TERN


Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?

Nov 25, 2025, 2:38 PM EST - 4 weeks ago

Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?


Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Aug 18, 2025, 8:00 AM EDT - 4 months ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer


Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript

May 13, 2025, 11:15 AM EDT - 8 months ago

Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript


Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 12:06 PM EDT - 10 months ago

Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript


Legend Biotech: The Story Brightens

Dec 5, 2024, 2:14 PM EST - 1 year ago

Legend Biotech: The Story Brightens


Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Nov 4, 2024, 7:30 AM EST - 1 year ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®


Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:41 AM EDT - 1 year ago

Legend Biotech to set up new R&D facility in Philadelphia


Night_Owl_Biotech
Night_Owl_Biotech Dec. 23 at 10:19 PM
Commercial-stage oncology focused bio valuation related data points for those with market caps north of $1.5B $SNDX is up sharply the last 5 months. In early August 2025, investors could buy SNDX for $10/share. Since the ASH presentations, the market appears more confident longer-term revenue estimates are attainable. All the same, at $22 a share SNDX still trades at meaningfully lower multiples of projected revenues than the others in this specific peer group. $INCY could, in theory, buy SNDX for 4.0X FY29 revenue estimates consistent with peer M&A revenue multiples paid. Should INCY maintain a 4.2X FY29 revenue multiple the acquisition would, again in theory, be accretive to INCY shareholders. $LEGN valuation continues to suffer in light of $JNJ recent combo drug data that meaningfully outperformed Carvykti in R/R MM. It's been 2 weeks & we're unaware of any reduction in LEGN analyst projections (we could be wrong). This is not investment advice (especially LEGN). $XBI
1 · Reply
The_Scientist
The_Scientist Dec. 22 at 9:08 PM
$LEGN remember at these prices you will hold gold. Don't give up 🙏🏽
0 · Reply
doodoodeity
doodoodeity Dec. 22 at 4:07 PM
$LEGN taking a starter here, more near 21
0 · Reply
Nikolay27
Nikolay27 Dec. 21 at 6:17 PM
0 · Reply
Nikolay27
Nikolay27 Dec. 21 at 6:16 PM
0 · Reply
The_Scientist
The_Scientist Dec. 19 at 6:42 PM
$LEGN patience family the crackheads at Wall Street will allow it to run up soon. Just hold through difficult times 🙏🏽. Stay strong.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:54 PM
Actionable Trade Alert for $LEGN: Market Context: $LEGN is currently trading at $21.28, significantly below its 60-day high of $34.8, indicating potential for upward movement. The RSI at 15.47 suggests the stock is oversold, which may lead to a price correction. Directional Bias: The stock's proximity to its 60-day low of $21.19 and the low RSI indicates a strong potential for a rebound. Additionally, both the 30-day (27.2) and 50-day (29.26) moving averages are well above the current price, which could act as resistance levels. Trade Plan: - Suggested Entry: $21.30 - Stop Loss: $20.50 (approximately 3.75% risk) - Take Profit Targets: 1. $24.00 (Target 1, 12.7% ROI) 2. $26.00 (Target 2, 22.5% ROI) 3. $25.00 (Target 3, 17.6% ROI) With this plan, we aim for a minimum of 17% ROI on the third target while managing risk effectively. https://privateprofiteers.com
0 · Reply
WolfofWallasey
WolfofWallasey Dec. 19 at 4:46 PM
Almost Christmas My current plays are $MIGI which I think could rip faces any moment $CRWD safe long term set and forget $LEGN set and forget and she’s about to become profitable Peace ✌️
0 · Reply
Tigerpicko
Tigerpicko Dec. 19 at 3:52 PM
$LEGN bring on Q1 2026
0 · Reply
Himster
Himster Dec. 19 at 1:46 PM
$LEGN company is projected to be profitable next year..
0 · Reply
Tigerpicko
Tigerpicko Dec. 18 at 8:48 PM
$LEGN losing streak always will be until in profit just await Q1 no pint messagingthis and that just wait then bang massive news
0 · Reply
pole0102
pole0102 Dec. 18 at 8:46 PM
$LEGN A 9 day losing streak since ASH. Make that ten by tomorrow.
0 · Reply
Megabuxs
Megabuxs Dec. 18 at 6:52 PM
$LEGN starting to accumulate
0 · Reply
Tigerpicko
Tigerpicko Dec. 17 at 8:08 PM
$LEGN that’s the massive stop loss reached $21.5 bring on Q1 2026 going to be a great year
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:07 PM
Cantor Fitzgerald updates rating for Legend Biotech ( $LEGN ) to Overweight, target set at 75 → 74.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:39 AM
Actionable Trade Alert for $LEGN: Market Context: $LEGN is currently trading at $21.65, significantly below its 60-day high of $34.8, indicating potential for upward movement. The RSI at 16.77 suggests the stock is oversold, signaling a possible reversal. Directional Bias: The stock is underperforming relative to its moving averages (MA30 at 27.91 and MA50 at 29.68), indicating bearish momentum. However, the extreme RSI level and proximity to the 60-day low of $21.51 suggest a strong potential for a bounce back. Trade Plan: - Suggested Entry: $21.70 (slightly above the last close) - Stop Loss: $21.50 (to limit downside risk) - Take Profit Targets: 1. Target 1: $24.00 (11% ROI) 2. Target 2: $26.00 (20% ROI) 3. Target 3: $25.40 (17% ROI) With the potential for a rebound supported by the oversold RSI, this trade offers a favorable risk-reward setup. Monitor closely for market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
1 · Reply
pole0102
pole0102 Dec. 16 at 7:22 PM
$LEGN will it ever go up again?
2 · Reply
BigTree79
BigTree79 Dec. 16 at 2:40 PM
$LEGN I think this is the bottom
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:11 AM
Actionable Trade Alert for $LEGN: Market Context: $LEGN is currently trading at $22.32, near its 60D low of $22.27. The RSI at 23.95 indicates that the stock is oversold, suggesting potential for a rebound. The moving averages (MA30 at 28.61 and MA50 at 30.08) indicate a bearish trend, but the proximity to the low and oversold RSI signal a possible reversal. Directional Bias: Bullish. The oversold RSI suggests buying pressure may emerge, and the stock's recent low could act as a support level. Trade Plan: - Suggested Entry: $22.50 - Stop Loss: $21.50 (risking $1.00) - Take Profit Targets: 1. $25.00 (11.1% ROI) 2. $28.00 (24.8% ROI) 3. $26.00 (15.5% ROI) With a potential to achieve over 17% ROI on the third target, this trade presents a favorable risk-reward setup. Monitor for market sentiment shifts that may impact price movement. https://privateprofiteers.com
0 · Reply
Mtango
Mtango Dec. 14 at 10:36 PM
$LEGN @They_Call_Me_Tater_Salad this one looks massively oversold (well below target prices and below the cost basis of most institutional investors). Does this one seem interesting to you?
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 14 at 3:07 PM
On 12/9/25 $JNJ issued a press release disclosing the results of their Phase 3 clinical trial of their new combo therapy (name is too long to repeat here) in R/R multiple myeloma. Apparently, J&J had presented at ASH. The J&J combo drug appears to produce meaningfully better clinical outcomes in R/R (relapsed/refractory) multiple myeloma compared to Carvykti from $LEGN The attachment compares the key clinical data points from the 2 trials side-by-side (at least as we see them). It was puzzling to see Morgan Stanley recommend LEGN last Friday after reviewing these data points. Based on these results, we suspect J&J will push their new combo therapy (if approved) versus Carvykti. While the brutal truth is there are enough multiple myeloma patients for multiple therapies, it is likely the clinical differences will eventually manifest in lower LEGN revenue estimates (thus raising multiples). Pushback welcome. Did we miss any clinical data point (outside of side-effects) More to come. $XBI $IBB
3 · Reply
BigTree79
BigTree79 Dec. 13 at 6:01 PM
$LEGN wheres the bottom?
0 · Reply